Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OK's Silvergate's Epaned; new ped hypertension option

This article was originally published in Scrip

Executive Summary

The US FDA has granted Silvergate Pharmaceuticals approval to market Epaned (enalapril maleate) powder for oral solution to treat high blood pressure for patients as young as one month – providing not only a new option for adults who may have difficulty swallowing pills, but also for babies and children with pediatric hypertension.

Related Content

Topics

UsernamePublicRestriction

Register

SC022431

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel